Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseases, today announced that management will participate in the following upcoming investor conferences:
Event: TD Cowen 45th Annual Healthcare ConferenceFormat: Fireside chat and 1×1 meetingsDate/Time: Tuesday, March 4, 2025 at 3:10pm ETLocation: Boston, MA
Event: Jefferies Biotech on the Beach SummitFormat: 1×1 meetingsDate: Tuesday, March 11, 2025Location: Miami, FL
Live audio webcasts and replays of the TD Cowen fireside event will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.
About Spyre TherapeuticsSpyre Therapeutics is a biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations. Spyre's pipeline includes extended half-life antibodies targeting a4B7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com.
https://mma.prnewswire.com/media/2286436/Spyre_Therapeutics_Inc_Logo.jpg
https://c212.net/c/img/favicon.png?sn=DA25572&sd=2025-02-25
View original content to download multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-to-participate-in-upcoming-march-investor-conferences-302383597.html
SOURCE Spyre Therapeutics, Inc.
https://rt.newswire.ca/rt.gif?NewsItemId=DA25572&Transmission_Id=202502250800PR_NEWS_USPR_____DA25572&DateId=20250225